Voyager Therapeutics (VYGR) Competitors $5.11 +0.16 (+3.13%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. UPB, RLAY, SPRY, SEPN, SANA, BCAX, COLL, PHAR, XNCR, and CRONShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Upstream Bio (UPB), Relay Therapeutics (RLAY), ARS Pharmaceuticals (SPRY), Septerna (SEPN), Sana Biotechnology (SANA), Bicara Therapeutics (BCAX), Collegium Pharmaceutical (COLL), Pharming Group (PHAR), Xencor (XNCR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Its Competitors Upstream Bio Relay Therapeutics ARS Pharmaceuticals Septerna Sana Biotechnology Bicara Therapeutics Collegium Pharmaceutical Pharming Group Xencor Cronos Group Voyager Therapeutics (NASDAQ:VYGR) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Does the media prefer VYGR or UPB? In the previous week, Upstream Bio had 7 more articles in the media than Voyager Therapeutics. MarketBeat recorded 7 mentions for Upstream Bio and 0 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.51 beat Upstream Bio's score of 0.49 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Voyager Therapeutics Positive Upstream Bio Neutral Do insiders & institutionals hold more shares of VYGR or UPB? 48.0% of Voyager Therapeutics shares are held by institutional investors. 4.5% of Voyager Therapeutics shares are held by insiders. Comparatively, 13.6% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate VYGR or UPB? Voyager Therapeutics presently has a consensus price target of $12.96, suggesting a potential upside of 153.77%. Upstream Bio has a consensus price target of $53.33, suggesting a potential upside of 139.86%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Upstream Bio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable valuation & earnings, VYGR or UPB? Upstream Bio has lower revenue, but higher earnings than Voyager Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$80M3.54-$65M-$1.85-2.76Upstream Bio$2.37M505.78-$62.81MN/AN/A Is VYGR or UPB more profitable? Voyager Therapeutics has a net margin of -253.49% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat Voyager Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-253.49% -37.65% -28.89% Upstream Bio -3,836.58%-35.90%-26.26% SummaryVoyager Therapeutics beats Upstream Bio on 7 of the 13 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$281.51M$3.47B$6.17B$10.68BDividend YieldN/A2.27%5.72%4.83%P/E Ratio-2.7423.4029.4727.34Price / Sales3.54479.21587.77132.79Price / CashN/A45.2825.8230.35Price / Book0.9310.5212.446.68Net Income-$65M-$52.71M$3.32B$276.46M7 Day Performance4.40%4.72%2.15%0.77%1 Month Performance19.56%15.59%8.41%3.73%1 Year Performance-36.74%13.83%61.67%36.59% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics4.3711 of 5 stars$5.11+3.1%$12.96+153.8%-38.7%$281.51M$80M-2.74100UPBUpstream Bio1.9619 of 5 stars$20.08+2.3%$56.50+181.4%-19.0%$1.08B$2.37M0.0038RLAYRelay Therapeutics2.1716 of 5 stars$6.27-3.5%$16.50+163.2%-3.6%$1.08B$8.36M-3.22330Positive NewsSPRYARS Pharmaceuticals2.9749 of 5 stars$10.93-3.4%$33.80+209.2%-37.1%$1.08B$89.15M-22.3190SEPNSepterna1.3607 of 5 stars$24.09+4.4%$26.75+11.0%N/A$1.07B$726K-2.39N/ASANASana Biotechnology2.8154 of 5 stars$4.34+0.5%$7.50+72.8%+18.9%$1.03BN/A-4.09380Gap UpBCAXBicara Therapeutics2.43 of 5 stars$18.51+4.1%$31.86+72.1%-16.9%$1.01BN/A-5.8432Gap UpCOLLCollegium Pharmaceutical3.9435 of 5 stars$32.04flat$42.33+32.1%-11.7%$1.01B$707.01M30.81210Analyst DowngradePHARPharming Group2.8055 of 5 stars$14.61+2.4%$30.00+105.3%+52.8%$1.00B$297.20M-112.38280Positive NewsUpcoming EarningsShort Interest ↓Gap DownHigh Trading VolumeXNCRXencor3.7379 of 5 stars$13.96+7.1%$24.22+73.5%-32.2%$995.67M$146.93M-5.82280CRONCronos Group1.0266 of 5 stars$2.55+1.6%N/A+14.2%$976.38M$130.28M51.00450Positive News Related Companies and Tools Related Companies Upstream Bio Alternatives Relay Therapeutics Alternatives ARS Pharmaceuticals Alternatives Septerna Alternatives Sana Biotechnology Alternatives Bicara Therapeutics Alternatives Collegium Pharmaceutical Alternatives Pharming Group Alternatives Xencor Alternatives Cronos Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
